JP2021533206A - フッ素化胆汁酸誘導体 - Google Patents
フッ素化胆汁酸誘導体 Download PDFInfo
- Publication number
- JP2021533206A JP2021533206A JP2021529531A JP2021529531A JP2021533206A JP 2021533206 A JP2021533206 A JP 2021533206A JP 2021529531 A JP2021529531 A JP 2021529531A JP 2021529531 A JP2021529531 A JP 2021529531A JP 2021533206 A JP2021533206 A JP 2021533206A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- ethyl
- general formula
- fluoro
- dihydroxyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 C[C@](CC1)(C(CC2)C(C(*)[C@@]3*)C1[C@@](C)(C[C@]1(C)*)[C@@]3(*3)[C@]3(*)[C@]1([*+2])O)[C@@]2[C@@](**)S Chemical compound C[C@](CC1)(C(CC2)C(C(*)[C@@]3*)C1[C@@](C)(C[C@]1(C)*)[C@@]3(*3)[C@]3(*)[C@]1([*+2])O)[C@@]2[C@@](**)S 0.000 description 8
- QIZHYMSGSDCWHP-LOTHRFMXSA-N CC[C@@H]([C@H](C(C(CC1)[C@](C)(CC2)C1[C@H](C)CCN=C=O)C2[C@@]1(C)CC[C@H]2OC(C)=O)O)[C@@H]1C2(F)F Chemical compound CC[C@@H]([C@H](C(C(CC1)[C@](C)(CC2)C1[C@H](C)CCN=C=O)C2[C@@]1(C)CC[C@H]2OC(C)=O)O)[C@@H]1C2(F)F QIZHYMSGSDCWHP-LOTHRFMXSA-N 0.000 description 1
- RSOSTVAVYGKDQE-PBWHPJSFSA-N CC[C@@H]([C@H](C(C(CC1)[C@](C)(CC2)C1[C@H](C)CCNC(NS(c1ccccc1)(=O)=O)=O)C2[C@@]1(C)CC[C@H]2OC(C)=O)O)[C@@H]1C2(F)F Chemical compound CC[C@@H]([C@H](C(C(CC1)[C@](C)(CC2)C1[C@H](C)CCNC(NS(c1ccccc1)(=O)=O)=O)C2[C@@]1(C)CC[C@H]2OC(C)=O)O)[C@@H]1C2(F)F RSOSTVAVYGKDQE-PBWHPJSFSA-N 0.000 description 1
- CTWKPIFGDHHARY-GBNZCLLDSA-N CC[C@@H]1[C@](C)([C@H]([C@@H](CC2)O)F)C2(C)C(CC[C@@]2(C)C3CCC2[C@H](C)CCNC(NS(c2ccc(C(C)(C)C)cc2)(=O)=O)=O)C3[C@@H]1O Chemical compound CC[C@@H]1[C@](C)([C@H]([C@@H](CC2)O)F)C2(C)C(CC[C@@]2(C)C3CCC2[C@H](C)CCNC(NS(c2ccc(C(C)(C)C)cc2)(=O)=O)=O)C3[C@@H]1O CTWKPIFGDHHARY-GBNZCLLDSA-N 0.000 description 1
- QEQVGNROPDBKBF-YVFVLNLBSA-N CC[C@H]([C@H](C1)[C@@](C)(C(CC2)C3C(CC4)[C@@]2(C)[C@H]4[C@H](C)CCC(OC)=O)C=C[C@@H]1O)C3=O Chemical compound CC[C@H]([C@H](C1)[C@@](C)(C(CC2)C3C(CC4)[C@@]2(C)[C@H]4[C@H](C)CCC(OC)=O)C=C[C@@H]1O)C3=O QEQVGNROPDBKBF-YVFVLNLBSA-N 0.000 description 1
- IOXGXDFDKLBSDI-YPZTYZLDSA-N CC[C@H]([C@H](C[C@H]1O[C@H]1C1)[C@@]1(C)C(CC1)C2C(CC3)[C@@]1(C)[C@H]3[C@H](C)CCC(OC)=O)C2=O Chemical compound CC[C@H]([C@H](C[C@H]1O[C@H]1C1)[C@@]1(C)C(CC1)C2C(CC3)[C@@]1(C)[C@H]3[C@H](C)CCC(OC)=O)C2=O IOXGXDFDKLBSDI-YPZTYZLDSA-N 0.000 description 1
- WONWBUZGSFVWAH-MWRHKCAUSA-N CC[C@H]([C@H]([C@H]([C@@H](CC1)O)F)[C@@]1(C)C(CCCC1)C2C(CC3)[C@@H]1C3[C@H](C)CCNC(NS(c(cc1)ccc1OC)(=O)=O)=O)[C@H]2O Chemical compound CC[C@H]([C@H]([C@H]([C@@H](CC1)O)F)[C@@]1(C)C(CCCC1)C2C(CC3)[C@@H]1C3[C@H](C)CCNC(NS(c(cc1)ccc1OC)(=O)=O)=O)[C@H]2O WONWBUZGSFVWAH-MWRHKCAUSA-N 0.000 description 1
- WRCPBILGFWOIRL-FYZFRPPSSA-N CC[C@H]([C@H]([C@H]([C@@H](CC1)OC(C)=O)F)[C@@]1(C)C(CC1)C2C(CC3)[C@@]1(C)C3[C@H](C)CCNC(NS(c1ccc(C(C)(C)C)cc1)(=O)=O)=O)[C@H]2O Chemical compound CC[C@H]([C@H]([C@H]([C@@H](CC1)OC(C)=O)F)[C@@]1(C)C(CC1)C2C(CC3)[C@@]1(C)C3[C@H](C)CCNC(NS(c1ccc(C(C)(C)C)cc1)(=O)=O)=O)[C@H]2O WRCPBILGFWOIRL-FYZFRPPSSA-N 0.000 description 1
- RQFIPQFHTZJVQP-PQDZBGMNSA-N CC[C@H]([C@](C)(C[C@@H](C=CCC1)O)[C@@H]1C(CC1)C2C(CC3)[C@@]1(C)[C@H]3[C@H](C)CCC(OC)=O)C2=O Chemical compound CC[C@H]([C@](C)(C[C@@H](C=CCC1)O)[C@@H]1C(CC1)C2C(CC3)[C@@]1(C)[C@H]3[C@H](C)CCC(OC)=O)C2=O RQFIPQFHTZJVQP-PQDZBGMNSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024038682A JP2024088648A (ja) | 2018-07-30 | 2024-03-13 | フッ素化胆汁酸誘導体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1812382.8 | 2018-07-30 | ||
| GBGB1812382.8A GB201812382D0 (en) | 2018-07-30 | 2018-07-30 | Compounds |
| PCT/GB2019/052127 WO2020025942A1 (en) | 2018-07-30 | 2019-07-30 | Fluorinated bile acid derivatives |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024038682A Division JP2024088648A (ja) | 2018-07-30 | 2024-03-13 | フッ素化胆汁酸誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021533206A true JP2021533206A (ja) | 2021-12-02 |
| JPWO2020025942A5 JPWO2020025942A5 (enExample) | 2022-07-26 |
| JP7805783B2 JP7805783B2 (ja) | 2026-01-26 |
Family
ID=
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106083978A (zh) * | 2015-04-28 | 2016-11-09 | 上海迪诺医药科技有限公司 | 磺酰基氨基羰基衍生物、其药物组合物及应用 |
| CN106518946A (zh) * | 2015-09-10 | 2017-03-22 | 上海迪诺医药科技有限公司 | 磺酰脲衍生物、其药物组合物及应用 |
| JP2017533923A (ja) * | 2014-11-06 | 2017-11-16 | エナンタ ファーマシューティカルズ インコーポレイテッド | Ｆｘｒ／ｔｇｒ５アゴニストとしての胆汁酸類似体およびその使用方法 |
| JP2017535570A (ja) * | 2014-11-26 | 2017-11-30 | エナンタ ファーマシューティカルズ インコーポレイテッド | Ｆｘｒ／ｔｇｒ５アゴニストとしての胆汁酸類似体およびその使用方法 |
| JP2018519246A (ja) * | 2015-04-28 | 2018-07-19 | ジエンス ハンセン ファーマセウティカル グループ カンパニー リミテッド | コール酸誘導体、及びその製造方法及び医薬用途 |
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017533923A (ja) * | 2014-11-06 | 2017-11-16 | エナンタ ファーマシューティカルズ インコーポレイテッド | Ｆｘｒ／ｔｇｒ５アゴニストとしての胆汁酸類似体およびその使用方法 |
| JP2017535570A (ja) * | 2014-11-26 | 2017-11-30 | エナンタ ファーマシューティカルズ インコーポレイテッド | Ｆｘｒ／ｔｇｒ５アゴニストとしての胆汁酸類似体およびその使用方法 |
| CN106083978A (zh) * | 2015-04-28 | 2016-11-09 | 上海迪诺医药科技有限公司 | 磺酰基氨基羰基衍生物、其药物组合物及应用 |
| JP2018519246A (ja) * | 2015-04-28 | 2018-07-19 | ジエンス ハンセン ファーマセウティカル グループ カンパニー リミテッド | コール酸誘導体、及びその製造方法及び医薬用途 |
| CN106518946A (zh) * | 2015-09-10 | 2017-03-22 | 上海迪诺医药科技有限公司 | 磺酰脲衍生物、其药物组合物及应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112771063A (zh) | 2021-05-07 |
| WO2020025942A1 (en) | 2020-02-06 |
| EP3830103B1 (en) | 2023-11-08 |
| EP3830103A1 (en) | 2021-06-09 |
| US11517577B2 (en) | 2022-12-06 |
| EP3830103B8 (en) | 2023-12-20 |
| JP2024088648A (ja) | 2024-07-02 |
| GB201812382D0 (en) | 2018-09-12 |
| EP3830103C0 (en) | 2023-11-08 |
| CN112771063B (zh) | 2023-10-27 |
| US20210299148A1 (en) | 2021-09-30 |
| ES2968881T3 (es) | 2024-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024088648A (ja) | フッ素化胆汁酸誘導体 | |
| DK2997035T3 (en) | 11-HYDROXY-6-SUBSTITUTED BALIC ACID DERIVATIVES AND AMINO ACID CONJUGATES THEREOF AS FARNESOID X RECEPTOR MODULATORS | |
| CN106661079B (zh) | 用于治疗和/或预防fxr和tgr5/gpbar1介导的疾病的胆烷衍生物 | |
| CN108883305B (zh) | 3-脱氧衍生物及其药物组合物 | |
| JP2018530559A (ja) | ファルネソイドｘ受容体調節剤 | |
| JP7805783B2 (ja) | フッ素化胆汁酸誘導体 | |
| Ko et al. | Galangin 3-benzyl-5-methylether derivatives function as an adiponectin synthesis-promoting peroxisome proliferator-activated receptor γ partial agonist | |
| Ding et al. | Andrographolide derivative as antagonist of vitamin D receptor to induce lipidation of microtubule associate protein 1 light chain 3 (LC3) | |
| HK40055914B (en) | Fluorinated bile acid derivatives | |
| HK40055914A (en) | Fluorinated bile acid derivatives | |
| EP3658566A2 (en) | Side-chain modified ergosterol and stigmasterol derivatives as liver x receptor modulators | |
| EP2583968B1 (en) | Compounds having activating effect on subtypes of peroxisome proliferator-activated receptors and its preparation method and uses | |
| JP2008214222A (ja) | フェノール誘導体及びその医薬用途 | |
| EP3160508B1 (en) | Novel rexinoid compounds and methods of using rexinoid compounds for treating metabolic disorders and cancer | |
| CN116120335A (zh) | 作为Wnt信号通路激动剂的莪术醇衍生物及其制法和应用 | |
| CN120574193A (zh) | 一种石竹烷衍生物及其制备方法和应用 | |
| HK1253326B (zh) | 作为法尼醇x受体调节剂的胆汁酸的11-羟基衍生物及其氨基酸共轭物 | |
| HK1259145B (zh) | 3-脱氧衍生物及其药物组合物 | |
| HK1221471B (en) | 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators | |
| HK1184155B (en) | Compounds having activating effect on subtypes of peroxisome proliferator-activated receptors and its preparation method and uses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220714 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220714 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230613 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20231114 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20240313 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240403 |
|
| RD13 | Notification of appointment of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7433 Effective date: 20250829 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260114 |